bullish
How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share
574 Views17 Aug 2020 21:37
CureVac stock closed at $55.90 per share during the first trading day, the best performance among biotech IPOs this year. Since the beginning of...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Price Chart(Sign Up to Access)
- Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies13 Nov 2020
- Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October28 Sep 2020
- CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech21 Aug 2020
- How High Can CureVac Stock Go After Blockbuster IPO? We Update Bull Case Scenario to $80 Per Share17 Aug 2020
- CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology14 Aug 2020
x